Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Colorcon
Dow
Harvard Business School
Merck

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR ELIQUIS


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Eliquis

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01675076 ↗ Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events Completed Bayer Phase 3 2013-01-01 The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma.
NCT01675076 ↗ Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events Completed Boehringer Ingelheim Phase 3 2013-01-01 The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma.
NCT01675076 ↗ Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events Completed Bristol-Myers Squibb Phase 3 2013-01-01 The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma.
NCT01675076 ↗ Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events Completed Heart and Stroke Foundation of Canada Phase 3 2013-01-01 The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma.
NCT01675076 ↗ Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events Completed Ottawa Heart Institute Research Corporation Phase 3 2013-01-01 The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eliquis

Condition Name

Condition Name for Eliquis
Intervention Trials
Venous Thromboembolism 15
Atrial Fibrillation 14
Pulmonary Embolism 6
Deep Vein Thrombosis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Eliquis
Intervention Trials
Atrial Fibrillation 20
Thromboembolism 19
Thrombosis 18
Venous Thromboembolism 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Eliquis

Trials by Country

Trials by Country for Eliquis
Location Trials
United States 262
Canada 35
United Kingdom 24
Germany 14
Switzerland 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Eliquis
Location Trials
California 11
Minnesota 11
North Carolina 10
Pennsylvania 10
Ohio 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Eliquis

Clinical Trial Phase

Clinical Trial Phase for Eliquis
Clinical Trial Phase Trials
Phase 4 19
Phase 3 16
Phase 2/Phase 3 3
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Eliquis
Clinical Trial Phase Trials
Completed 29
Recruiting 20
Unknown status 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Eliquis

Sponsor Name

Sponsor Name for Eliquis
Sponsor Trials
Bristol-Myers Squibb 29
Pfizer 9
Canadian Institutes of Health Research (CIHR) 6
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Eliquis
Sponsor Trials
Other 148
Industry 46
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKinsey
Merck
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.